Results 111 to 120 of about 1,525 (166)
Some of the next articles are maybe not open access.
3‐Quinuclidinyl benzilate (agent BZ) toxicokinetics in rats
Basic and Clinical Pharmacology and Toxicology, 2021Abstract3‐Quinuclidinyl benzilate (BZ) ranks among incapacitating military warfare agents. It acts as a competitive inhibitor on muscarinic receptors leading to non‐lethal mental impairment. The present study aimed to investigate toxicokinetics of BZ in rats. Moreover, BZ can be exploited to produce a pharmacological model of Alzheimer's disease; thus,
Alžbeta Dlabková +2 more
exaly +3 more sources
In Vivo Competition Studies with Analogues of 3-Quinuclidinyl Benzilate
Journal of Pharmaceutical Sciences, 1984Among ligands that bind to the alpha- and beta-adrenoceptors and to the muscarinic acetylcholine receptor (m-AChR), those that bind to the latter have the best properties for external detection of receptor sites by gamma-camera imaging. To develop the optimal radiotracer, nonradioactive analogues of 3-quinuclidinyl benzilate (I) were tested in in vivo ...
William C Eckelman +2 more
exaly +3 more sources
Quinuclidinyl Benzilate Binding in House Fly Heads and Rat Brain
Journal of Neurochemistry, 1981Abstract: House fly heads contain a binding site for 3‐quinuclidinyl benzilate (QNB) that is quite similar in pharmacology to the muscarinic acetylcholine receptor of vertebrate tissues. The house fly site binds [3H]QNB reversibly with a Kd of 260 PM and Bmax of 1 pmol/g of heads from direct binding measurements.
Katumi Sumikawa
exaly +3 more sources
Binding of [3H]quinuclidinyl Benzilate to regions of rat pituitary and hypothalamus
Brain Research Bulletin, 1981Muscarinic ligand binding sites in fragments of rat hypothalamus and pituitary were studied using [3H]quinuclidinyl benzilate (QNB). In the hypothalamus, the highest amount of specific QNB binding was to n. paraventricularis and n. dorsomedialis. Specific QNB binding in other hypothalamic regions varied within a relatively narrow range.
Donald B Hoover, John C Hancock
exaly +4 more sources
In vitro and in vivo metabolism of 3-quinuclidinyl benzilate by high-resolution mass spectrometry
Journal of Pharmaceutical and Biomedical Analysis, 20203-Quinuclidinyl benzilate (QNB) is an anticholinergic compound that affects the nervous system. Its hallucinogenic action has led to its potential utility as an incapacitating warfare agent, and it is listed in Schedule 2 by the Organization for the Prohibition of Chemical Weapons.
Martin Mzik +2 more
exaly +3 more sources
Parametric studies on phencyclidine enhancement of 3H quinuclidinyl Benzilate accumulation in vitro
Pharmacology Biochemistry and Behavior, 1988The purpose of these experiments was to define the temporal parameters involved in the phencyclidine (PCP) enhancement of 3H quinuclidinyl benzilate (QNB) accumulation in mouse brain. PCP enhanced QNB accumulation in brain if given intraperitoneally (IP) 1 and 4, but not 16 hours before intravenous (IV) administration of QNB.
Lawrence D Middaugh
exaly +3 more sources
Brain Research, 1984
Systemic injection of quinuclidinyl benzilate partially abolished low voltage fast activity (LVFA) in the neocortex of waking rats, resulting in the appearance of large irregular slow waves during Type 2 behaviors (e.g. immobility, sniffing without head movement, face washing). These slow waves did not occur during Type 1 behavior (e.g.
Derrick F Macfabe, C H Vanderwolf
exaly +3 more sources
Systemic injection of quinuclidinyl benzilate partially abolished low voltage fast activity (LVFA) in the neocortex of waking rats, resulting in the appearance of large irregular slow waves during Type 2 behaviors (e.g. immobility, sniffing without head movement, face washing). These slow waves did not occur during Type 1 behavior (e.g.
Derrick F Macfabe, C H Vanderwolf
exaly +3 more sources
Neuropharmacology, 1989
Phencyclidine has been shown to enhance the specific binding of [3H]quinuclidinyl benzilate (QNB) in the brain of the mouse when both compounds are given in vivo. Since a variety of studies indicate that dopaminergic (DA) systems are involved in the action of phencyclidine, it seemed that DA systems might mediate the enhancement of the binding of QNB ...
L D Middaugh, Lawrence D Middaugh
exaly +3 more sources
Phencyclidine has been shown to enhance the specific binding of [3H]quinuclidinyl benzilate (QNB) in the brain of the mouse when both compounds are given in vivo. Since a variety of studies indicate that dopaminergic (DA) systems are involved in the action of phencyclidine, it seemed that DA systems might mediate the enhancement of the binding of QNB ...
L D Middaugh, Lawrence D Middaugh
exaly +3 more sources
Brain Research, 1999
Gerbil vestibular tissues were isolated by microdissection and incubated in vitro with 3H-quinuclidinyl benzilate (3H-QNB). Control tissues were incubated in medium containing unlabeled atropine to differentiate non-specific from specific binding. Autoradiographic grain densities were determined by morphometric techniques and evaluated by two-tailed t ...
Dennis G Drescher +2 more
exaly +3 more sources
Gerbil vestibular tissues were isolated by microdissection and incubated in vitro with 3H-quinuclidinyl benzilate (3H-QNB). Control tissues were incubated in medium containing unlabeled atropine to differentiate non-specific from specific binding. Autoradiographic grain densities were determined by morphometric techniques and evaluated by two-tailed t ...
Dennis G Drescher +2 more
exaly +3 more sources
[3H]quinuclidinyl benzilate binding to the human lung muscarinic receptor
Biochemical Pharmacology, 1988Thomas B Casale
exaly +3 more sources